Division of Hologic Inc.
Latest From BioLucent Inc.
Highlights from the Q2 2008 review of device and diagnostics dealmaking: financing for medical device firms was down 9% from the first quarter to $838mm, which consisted mainly of late-stage venture rounds at 43% of the total. Big Pharma was surprisingly active in device acquisitions, with Novartis buying 25% of surgical instruments maker Alcon, and BMS selling off ConvaTec to private equity as part of its "string of pearls" strategy to focus on biotech. Two FOPOs dominated the $300mm financing the IVD/Research industry, while Invitrogen's $6.4bn stock swap for Applera's Applied Biosystems represented 90% of the M&A dollar volume.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for April-June 2007. Our data are derived from Windhover's Strategic Transactions Database.
Brief summaries of recent product and company developments in the device industry, including the demise of GE's proposed $8 billion acquisition of Abbott Diagnosticss, the Cytyc/Hologic merger, and Alsius' SPAC merger.
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- Hologic Inc.
- Senior Management
Steven L Gex, CEO
Hugh Neuharth, CFO
Charles Bracken, VP, Sales
- Contact Info
Phone: (949) 349-1380
Aliso Viejo, CA 92656
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.